Different clinical trials indicated a beneficial effect of GLP-1 analogs on obesity; thus, liraglutide was also licensed as a weight loss agent, with encouraging results in phase III clinical trials [34,52]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.